A clinical protocol for a German birth cohort study of the Maturation of Immunity Against respiratory viral Infections (MIAI)

Respiratory viral infections (RVIs) are a major global contributor to morbidity and mortality. The susceptibility and outcome of RVIs are strongly age-dependent and show considerable inter-population differences, pointing to genetically and/or environmentally driven developmental variability. The fa...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 15; p. 1443665
Main Authors: Hartmann, Carina R, Khan, Robin, Schöning, Jennifer, Richter, Maximilian, Willers, Maike, Pirr, Sabine, Heckmann, Julia, Dirks, Johannes, Morbach, Henner, Konrad, Monika, Fries, Elena, Winkler, Magdalene, Büchel, Johanna, Seidenspinner, Silvia, Fischer, Jonas, Vollmuth, Claudia, Meinhardt, Martin, Marissen, Janina, Schmolke, Mirco, Haid, Sibylle, Pietschmann, Thomas, Backes, Simone, Dölken, Lars, Löber, Ulrike, Keil, Thomas, Heuschmann, Peter U, Wöckel, Achim, Sagar, Ulas, Thomas, Forslund-Startceva, Sofia K, Härtel, Christoph, Viemann, Dorothee
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 17-09-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Respiratory viral infections (RVIs) are a major global contributor to morbidity and mortality. The susceptibility and outcome of RVIs are strongly age-dependent and show considerable inter-population differences, pointing to genetically and/or environmentally driven developmental variability. The factors determining the age-dependency and shaping the age-related changes of human anti-RVI immunity after birth are still elusive. We are conducting a prospective birth cohort study aiming at identifying endogenous and environmental factors associated with the susceptibility to RVIs and their impact on cellular and humoral immune responses against the influenza A virus (IAV), respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The MIAI birth cohort enrolls healthy, full-term neonates born at the University Hospital Würzburg, Germany, with follow-up at four defined time-points during the first year of life. At each study visit, clinical metadata including diet, lifestyle, sociodemographic information, and physical examinations, are collected along with extensive biomaterial sampling. Biomaterials are used to generate comprehensive, integrated multi-omics datasets including transcriptomic, epigenomic, proteomic, metabolomic and microbiomic methods. The results are expected to capture a holistic picture of the variability of immune trajectories with a focus on cellular and humoral key players involved in the defense of RVIs and the impact of host and environmental factors thereon. Thereby, MIAI aims at providing insights that allow unraveling molecular mechanisms that can be targeted to promote the development of competent anti-RVI immunity in early life and prevent severe RVIs. https://drks.de/search/de/trial/, identifier DRKS00034278.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Simon Daniel Van Haren, Boston Children’s Hospital and Harvard Medical School, United States
These authors have contributed equally to this work and share senior authorship
These authors have contributed equally to this work and share first authorship
Edited by: Joann Diray-Arce, Harvard Medical School, United States
Reviewed by: Lance Kendall Blevins, Michigan State University, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1443665